Key result
VTE shows no association with survival time in patients with lung cancer.
Why the study?
Lung cancer is the leading cause of cancer death in Japan, and foreign studies report a 4%-20% VTE rate, but the incidence in Japanese patients was unclear.
What is the incidence of venous thromboembolism and its associated clinical characteristics in patients with lung cancer in Japan?
Cohort (n=1,471)
No
What is the incidence of venous thromboembolism and its associated clinical characteristics in patients with lung cancer in Japan?
In Japanese patients with lung cancer, VTE is associated with younger age, advanced disease stage, and receipt of chemotherapy or radiation, and carries a high 1-year mortality rate of 60.7%.
VTE incidence data in Japanese lung cancer merit clinical awareness; extends international estimates but leaves open need for prospective validation.
Lung cancer is the leading cause of death from cancer in Japan. Studies in other countries have reported a venous thromboembolism (VTE) rate of 4%-20% in cancer patients. In this study, we aimed to determine the incidence of VTE in lung cancer patients in Japan and compared the characteristics of patients with and without VTE. In this retrospective cohort study, the clinicopathological characteristics of study patients with and without concomitant VTE were compared. Patients with lung cancer treated at Fukui Prefectural Hospital, Japan from 2008 to 2017. Of the 1471 patients with lung cancer studied, 28 developed VTE. Five patients developed pulmonary thromboembolism (PTE) alone, 9 PTE with concomitant deep vein thrombosis, and 14 deep vein thrombosis alone. Compared with patients in the non-VTE group, the VTE group was significantly younger (mean value ± SD 66.3 ± 10.1 vs. 73.0 ± 10.6 years, p = 0.001), contained significantly more patients with stage IIIb-IV disease (p = 0.002), and had a significantly higher rate of chemotherapy (p < 0.001) and radiation therapy (p = 0.007). There was no significant difference in median survival time from lung cancer diagnosis between the VTE and non-VTE groups. The 1-year mortality rate after VTE diagnosis was 60.7%. Lung cancer was the most frequent cause of death, followed by infection and VTE. Several baseline characteristics differed between patients with and without VTE. The prognosis may worsen after development of VTE, suggesting that lung cancer patients should be carefully monitored for it.
No takes yet. Share an insight, caveat, or question.
Suzuki et al. (2020) conducted a cohort in Lung cancer (n=1,471). Lung cancer was evaluated on Venous thromboembolism (VTE) incidence. In a cohort of 1,471 patients with lung cancer, the incidence of venous thromboembolism was 1.9%, and median survival time did not significantly differ between patients with and without VTE.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: